

# Alessandro Armuzzi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7933703/alessandro-armuzzi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

5,873  
citations

34  
h-index

76  
g-index

147  
ext. papers

7,326  
ext. citations

4.4  
avg. IF

5.11  
L-index

#	Paper	IF	Citations
123	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 649-670	1.5	837
122	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 443-68	1.5	633
121	The molecular classification of the clinical manifestations of Crohn's disease. <i>Gastroenterology</i> , <b>2002</b> , 122, 854-66	13.3	524
120	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2779-2789	40	403
119	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 4-22	1.5	320
118	Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 30-5	6.9	253
117	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , <b>2020</b> , 69, 1213-1217	19.2	208
116	The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 163-9	6.1	206
115	Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 747-56	6.1	140
114	Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. <i>Digestion</i> , <b>2001</b> , 63, 1-7	3.6	139
113	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 155-168	1.5	122
112	Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. <i>Gut</i> , <b>2003</b> , 52, 1133-9	19.2	120
111	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 1-20	3.3	101
110	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 233-243	4.5	96
109	Review article: breath testing for human liver function assessment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1977-96	6.1	86
108	The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. <i>Tissue Antigens</i> , <b>2003</b> , 62, 527-35		79
107	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e623-9	1.5	67

106	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 822-30	13.6	63
105	Infliximab in the treatment of steroid-dependent ulcerative colitis. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2004</b> , 8, 231-3	2.9	61
104	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 880-8	6.1	60
103	Adalimumab in active ulcerative colitis: a "real-life" observational study. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 738-43	3.3	57
102	Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1065-72	4.5	56
101	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , <b>2011</b> , 26, 1435-44	3	56
100	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\alpha$ agents. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, 113-9	1.5	54
99	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor $\alpha$ agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 974-9	3.3	48
98	Anti TNF- $\alpha$ therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 223-233	5.1	47
97	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1368-74	4.5	45
96	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1079-1088	1.5	41
95	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 852-8	1.5	40
94	Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 777-82	3.3	38
93	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 963-8	3.3	36
92	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- $\alpha$ on the Liver. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	35
91	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 568-579	4.5	35
90	Non-Invasive assessment of human hepatic mitochondrial function through the $^{13}\text{C}$ -methionine breath test. <i>Scandinavian Journal of Gastroenterology</i> , <b>2000</b> , 35, 650-3	2.4	35
89	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 338-338	3.3	34

88	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 604-617	3.3	34
87	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 360-70	3.3	29
86	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1426-1432.e1	6.9	28
85	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 17-23	3.3	26
84	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 592-600	3.3	24
83	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 632-639	3.3	22
82	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 601-7	3.3	21
81	Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 4839-45	5.6	21
80	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 913-24	1.5	21
79	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1805-1812	4.5	19
78	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 400	5.6	18
77	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1189-1197	5.3	18
76	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 941-950	6.1	17
75	A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, 421-6	1.5	15
74	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1086-1091	3.3	15
73	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> ,	1.5	15
72	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 653-660	3.3	14
71	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 972-977	3.3	13

70	Infliximab in Crohn's disease: early and long-term treatment. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40 Suppl 2, S271-9	3.3	12
69	Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 259-266	1.5	12
68	Therapeutic drug monitoring of anti-TNF- $\alpha$ agents in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1107-17	5.4	11
67	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , <b>2017</b> , 96, 166-172	3.6	11
66	Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 779-86	2.2	11
65	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , <b>2018</b> , 4, e000667	5.9	11
64	Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. <i>Digestive Diseases</i> , <b>2018</b> , 36, 184-193	3.2	10
63	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1298-1305	3.3	10
62	The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173664	3.7	10
61	Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 803-808	3.3	10
60	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 506-515	3.3	9
59	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , <b>2019</b> , 196, 123-138	6.2	9
58	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 613-620	3.3	8
57	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , <b>2020</b> , 69, 658-664	19.2	8
56	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 751-759	5.1	8
55	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. <i>Drug Design, Development and Therapy</i> , <b>2013</b> , 7, 289-96	4.4	8
54	Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102832	13.6	8
53	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211006669	4.7	7

52	Comment on: Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , <b>2019</b> , 58, 1113-1115	3.9	6
51	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , <b>2018</b> , 35, 545-562	4.1	6
50	Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1154-1161.e1	6.9	6
49	Etrolizumab in moderate-to-severe ulcerative colitis. <i>Lancet, The</i> , <b>2014</b> , 384, 285-6	4.0	6
48	Histopathology of inflammatory bowel disease - Position statement of the Pathologists of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Group of Gastrointestinal Pathologists (GIPAD-SIAPEC). <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 262-267	3.3	6
47	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <i>Gastroenterology Research and Practice</i> , <b>2018</b> , 2018, 4195968	2	6
46	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1259-1265	3.3	5
45	Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 273-280	6.1	5
44	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1304-1309	3.3	5
43	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI - San Marino" study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 218-225	3.3	5
42	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 212-217	3.3	5
41	P575 Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S398-S398	1.5	5
40	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , <b>2019</b> , 2019, 3108025	2	4
39	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
38	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	4
37	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
36	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 804-811	3.3	3
35	Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , <b>2016</b> , 8, 1-7	1.6	3



34	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , <b>2019</b> , 1, 93-99	1	2
33	Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	2
32	Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn. <i>Global &amp; Regional Health Technology Assessment</i> , <b>2017</b> , 4, grhta.5000258	0.2	2
31	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S029-S030	1.5	2
30	One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1483-1489	5.4	2
29	Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. <i>Journal of Advanced Nursing</i> , <b>2021</b> , 77, 2248-2266	3.1	2
28	The Determinants of Out-of-Pocket Expenditure in IBD Italian Patients. Results from the AMICI Survey. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	1
27	Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. <i>Reumatismo</i> , <b>2013</b> , 65, 75-8	1.1	1
26	IBD: Adalimumab for ulcerative colitis—is the glass half empty or half full?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2011</b> , 8, 249-51	24.2	1
25	Mucosal healing in ulcerative colitis: surveillance or colectomy?. <i>Annals of Gastroenterology</i> , <b>2013</b> , 26, 355	2.2	1
24	Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 764-765	6.1	1
23	Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e93-e94	4.5	1
22	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 97-104	5.4	1
21	Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNF therapy. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 729-737	3.3	0
20	Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2021</b> , 11, 889-891.e6	7.9	0
19	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 507-516	5.3	0
18	Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 950-957	3.3	0
17	OP29 ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S021-S022	1.5	

16	P497 IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S360-S361	1.5
15	Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD). <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 928-930	3.3
14	Reply to Dr. Joob et al.'s letter. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e154	1.5
13	Reply to Dr. Kotze's and Dr. Yamamoto's letter. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e699	1.5
12	P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, S183-S184	1.5
11	Fecal calprotectin in Inflammatory Bowel Disease treated with anti-TNF agents. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, S39	4.5
10	DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2022</b> , 16, i116-i117	1.5
9	Integration of Surgery with Medical Therapy in Treating Anal Fistulas. <i>Coloproctology</i> , <b>2021</b> , 1-18	
8	Microscopic imaging of Inflammatory Bowel Disease (IBD) and Non-IBD Colitis on digital slides: The Italian Group-IBD Pathologists experience. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 153189	3.4
7	P535 Optimising vedolizumab in treatment sequences for Crohn's disease: Results from a simulation model using real-world evidence. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, S509-S509	1.5
6	P079 Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, S181-S181	1.5
5	PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , <b>2016</b> , 65, A88-A89	19.2
4	Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e49-e50	4.5
3	The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic. <i>Gastrointestinal Nursing</i> , <b>2022</b> , 20, 40-46	0.2
2	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-8	5.4
1	Integration of Surgery with Medical Therapy in Treating Anal Fistulas. <i>Coloproctology</i> , <b>2022</b> , 519-536	